---
title: "Accuray Faces Nasdaq Delisting Risk as Shares Fall Below $1 Minimum Bid Price"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285675644.md"
description: "Accuray Incorporated (ARAY) is at risk of delisting from Nasdaq after its shares fell below the $1 minimum bid price for 30 consecutive business days. The company has a 180-day compliance period to restore the bid price. Failure to do so may lead to trading on over-the-counter markets, reducing liquidity and analyst coverage, which could further depress stock prices and hinder capital raising efforts. Currently, Wall Street holds a consensus rating of Hold on ARAY stock."
datetime: "2026-05-08T06:01:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285675644.md)
  - [en](https://longbridge.com/en/news/285675644.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285675644.md)
---

# Accuray Faces Nasdaq Delisting Risk as Shares Fall Below $1 Minimum Bid Price

Accuray Incorporated (ARAY) has disclosed a new risk, in the Share Price & Shareholder Rights category.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Accuray Incorporated faces a significant listing risk after receiving notice from Nasdaq that its shares failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days, triggering a 180-day compliance period. If the company cannot restore the bid price to at least $1.00 for the required duration, it could lose its Nasdaq Global Select Market listing and face severe market and financing constraints.

An eventual delisting would likely push trading of Accuray’s common stock to over-the-counter venues, reducing liquidity, weakening price discovery, and potentially limiting analyst coverage. Such developments could depress the stock price further and impair the company’s ability to raise capital on acceptable terms, amplifying financial and strategic risks for existing and prospective shareholders.

Overall, Wall Street has a Hold consensus rating on ARAY stock based on 1 Hold.

To learn more about Accuray Incorporated’s risk factors, click here.

### Related Stocks

- [ARAY.US](https://longbridge.com/en/quote/ARAY.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [Jenscare’s LuX-Valve Plus Shows Strong One-Year Results in Large Annulus Tricuspid Patients](https://longbridge.com/en/news/287144318.md)
- [Edwards Lifesciences CVP, Strategy/Corp Development Sold Shares Worth Over $1.4M](https://longbridge.com/en/news/286822028.md)
- [Final trade: CEG, GLD, NDAQ, CLF](https://longbridge.com/en/news/286825386.md)
- [Orthofix Medical updates 2026 outlook after CMS Medicare cuts for bone growth stimulators](https://longbridge.com/en/news/287216169.md)
- [Analyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16](https://longbridge.com/en/news/286945953.md)